A novel
neuregulin isoform, termed
gamma-HRG, was cloned and characterized from the human
breast cancer cell line, MDA-MB-175. As observed with other
neuregulins,
gamma-HRG, is a product of alternative
mRNA splicing of the
neuregulin gene.
Gamma-HRG contains the
EGF-like and immunoglobulin-like domains that are commonly found in other family members, but lacks a transmembrane and cytoplasmic region. The new
isoform possesses a unique N-terminal region that includes a hydrophobic domain that may function as a secretion signal. A purified recombinant version of
gamma-HRG competes for binding to soluble ErbB3- and ErbB4-IgG fusion
proteins with affinities similar to those observed for rHRGbeta1(177-244).
Gamma-HRG has a wide distribution in mesenchymal or neuronal tissues but in contrast to other
neuregulins, it is not present in breast, lung, liver and small intestine. Expression of
gamma-HRG with its cognate receptors, ErbB3 and ErbB2 suggested that the growth of the MDA-MB-175 cell line might be a result of the autocrine stimulation of a
growth factor signaling pathway. Treatment of MDA-MB-175 cells with an anti-ErbB2
monoclonal antibody that interferes with the
ligand-dependent formation of ErbB2-ErbB3 heterodimer complexes shows a strong growth inhibitory effect on this cell line. Moreover, incubation with a
receptor-IgG fusion
protein that neutralizes secreted
gamma-HRG, also inhibits cell growth. These data suggest that the secretion of
gamma-HRG by MDA-MB-175 cells leads to the formation of a constitutively active receptor complex and stimulates the growth of these cells in an autocrine manner.